New italian network aims to catch rare blood disease earlier
NCT ID NCT06383143
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is creating a network of hospitals in Italy to find and treat AL amyloidosis earlier. Researchers will screen people with certain blood conditions (MGUS or smoldering myeloma) using special tests. The goal is to speed up diagnosis, connect patients to the right care, and learn more about the disease. About 760 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera Policlinico Consorziale
RECRUITINGBari, Italy
-
Azienda Ospedaliero Universitaria Policlinico G.Rodolico - San Marco
RECRUITINGCatania, Italy
-
EMATOLOGIA - Città della Scienza e Salute - Torino
RECRUITINGTorino, Italy
-
Fondazione Irccs Policlinico San Matteo
RECRUITINGPavia, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- Gene clues may unlock new treatments for bone marrow cancer